OTC · ADTX

Aditxt, Inc.

Healthcare · Biotechnology

$0.01▼ 9.23% ($0.00)today

As of 1:10 PM ET

52-week

$0.00$26,604.72

Market cap

$5.89M

P/E

-0.00

Volume

9.49M

Shares outstanding

997.98M

Data caution

Per-share valuation inputs need verification

Event dated Mar 31, 2026

Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.

What the market price implies · Reverse DCF

Historical revenue grew by -58.24%/yr over the past 4 years.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.01

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-03-31

Enterprise value of $432.59K does not cover net debt of $1.14M, so equity value is negative and no fair value per share can be shown. The projected cash flows are positive; the shortfall is in the equity bridge, not the forecast. This engine cannot separate captive-finance or other non-operating borrowings from operating debt.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 40% · Ending margin 0% · Discount rate 14.22%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 15, 2026, 5:10 PM UTC
Financial statement period: TTM ending 2026-03-31
Data refreshed: Sep 15, 2026, 5:26 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: -100%Revenue (TTM): -74.09%FCF (TTM): 17.49%

What changed

The stock fell 100% over the last year. Revenue declined 74.09% over the trailing twelve months. Operating margin moved from -39,651.08% to -127,821.37%. Free cash flow grew 17.49% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -127,821.37%. Revenue declined 74.09% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques.

CEOJeffrey Busch

SectorHealthcare

IndustryBiotechnology

Employees26

IPO dateJun 30, 2020

https://www.aditxt.com

Market multiples

Forward P/E—

EV/EBITDA-0.16

Enterprise value$6.55M

Stock splits

May 18, 2026↓ Reverse

Every 27 shares became 1

-96%

Mar 9, 2026↓ Reverse

Every 8 shares became 1

-87%

Nov 3, 2025↓ Reverse

Every 113 shares became 1

-99%

Mar 17, 2025↓ Reverse

Every 250 shares became 1

-100%

Oct 2, 2024↓ Reverse

Every 40 shares became 1

-97%

Aug 18, 2023↓ Reverse

Every 40 shares became 1

-97%

Sep 14, 2022↓ Reverse

Every 50 shares became 1

-98%

Profitability & growth

Revenue growth1,094.4%

Gross margin (FY2025)8.39%▲376.3ppvs FY2024

Operating margin (FY2025)-612,542.22%▼591745.9ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$1,280.00▲21694815.25%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Dec 2, 2026

Q3 FY26 · EPS est -$24,408,000,000.00 · Revenue est $1M

View

OTC · ADTX

Aditxt, Inc.

Healthcare · Biotechnology

$0.01▼ 9.23% ($0.00)today

As of 1:10 PM ET

52-week

$0.00$26,604.72

Market cap

$5.89M

P/E

-0.00

Volume

9.49M

Shares outstanding

997.98M

Data caution

Per-share valuation inputs need verification

Event dated Mar 31, 2026

What the market price implies · Reverse DCF

Historical revenue grew by -58.24%/yr over the past 4 years.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.01

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-03-31

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 40% · Ending margin 0% · Discount rate 14.22%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 15, 2026, 5:10 PM UTC
Financial statement period: TTM ending 2026-03-31
Data refreshed: Sep 15, 2026, 5:26 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: -100%Revenue (TTM): -74.09%FCF (TTM): 17.49%

What changed

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Performance

Return analysis

Company profile

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques.

CEOJeffrey Busch

SectorHealthcare

IndustryBiotechnology

Employees26

IPO dateJun 30, 2020

https://www.aditxt.com

Market multiples

Forward P/E—

EV/EBITDA-0.16

Enterprise value$6.55M

Stock splits

May 18, 2026↓ Reverse

Every 27 shares became 1

-96%

Mar 9, 2026↓ Reverse

Every 8 shares became 1

-87%

Nov 3, 2025↓ Reverse

Every 113 shares became 1

-99%

Mar 17, 2025↓ Reverse

Every 250 shares became 1

-100%

Oct 2, 2024↓ Reverse

Every 40 shares became 1

-97%

Aug 18, 2023↓ Reverse

Every 40 shares became 1

-97%

Sep 14, 2022↓ Reverse

Every 50 shares became 1

-98%

Profitability & growth

Revenue growth1,094.4%

Gross margin (FY2025)8.39%▲376.3ppvs FY2024

Operating margin (FY2025)-612,542.22%▼591745.9ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$1,280.00▲21694815.25%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Dec 2, 2026

Q3 FY26 · EPS est -$24,408,000,000.00 · Revenue est $1M

View